Safety and Effectiveness of TactiCath Contact Force Sensor Enabled (TactiCath SE) Catheter for Ablation of Drug Refractory Symptomatic Persistent Atrial Fibrillation (PERSIST-END Trial)

Brief description of study

The purpose of this research study is to demonstrate that the TactiCath SE catheter is safe and effective in the treatment of persistent Atrial Fibrillation (AF). Atrial fibrillation (AF) is caused by abnormal electrical signals in the upper chambers of the heart, called the atria, which cause them to beat rapidly and irregularly. When the atria beat rapidly and irregularly, they do not pump blood effectively. Cardiac ablation for persistent atrial fibrillation is a procedure that involves using a catheter to deliver radiofrequency energy to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter transmits energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat.


Clinical Study Identifier: s18-01408
ClinicalTrials.gov Identifier: NCT03650556
Principal Investigator: Larry A Chinitz
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.